To assess levels of expression of Claudin-5 with disease progression, Claudin-5 transcript levels in the breast cancer samples were analysed against The Nottingham Prognostic Index (NPI), tumour-node-metastasis (TNM) and histological grade. This evidence concerns the gene CLDN5 and breast cancer.